Sofosbuvir/velpatasvir/voxilaprevir for patients with chronic hepatitis C virus infection previously treated with NS5A direct-acting antivirals: a real-world multicenter cohort in Taiwan
暂无分享,去创建一个
J. Kao | Chun-Jen Liu | Y. Shih | Jyh-Jou Chen | Chi-Yang Chang | Jo-Hsuan Wu | W. Su | T. Hsieh | C. Peng | H. Lai | Chen‐Hua Liu | M. Tsai | Chih-Wei Tseng | P. Su | Ching-chu Lo | Pei‐Lun Lee | H. Tung | Sheng-Shun Yang | Ke-Jhang Huang | Chi-yi Chen | K. Tseng | F. Lee | W. Kao | Po-Yueh Chen | Yu-Jen Fang | Chia-Sheng Huang | Chun-Chao Chang | Yi‐Jie Huang | Jow-Jyh Hwang | Chung-Hsin Chang | Hao-Tsai Cheng | Wei-Yu Kao
[1] Wei Liu,et al. Effectiveness and Safety of Sofosbuvir/Velpatasvir/Voxilaprevir as a Hepatitis C Virus Infection Salvage Therapy in the Real World: A Systematic Review and Meta-analysis , 2022, Infectious Diseases and Therapy.
[2] Y. Wong,et al. Treatment outcomes of sofosbuvir/velpatasvir/voxilaprevir among NS5A inhibitor‐experienced patients with hepatitis C: Real‐world data from a multicenter Asian registry , 2022, Journal of gastroenterology and hepatology.
[3] Jessica R. Ackerman,et al. Retreatment for hepatitis C virus direct‐acting antiviral therapy virological failure in primary and tertiary settings: The REACH‐C cohort , 2022, Journal of viral hepatitis.
[4] T. Tseng,et al. Long-term evolution of estimated glomerular filtration rate in patients with antiviral treatment for hepatitis C virus infection. , 2022, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.
[5] Jisoo A. Kwon,et al. Global change in hepatitis C virus prevalence and cascade of care between 2015 and 2020: a modelling study. , 2022, The lancet. Gastroenterology & hepatology.
[6] S. Flamm,et al. Sofosbuvir/velpatasvir/voxilaprevir for hepatitis C virus retreatment in decompensated cirrhosis , 2021, Liver international : official journal of the International Association for the Study of the Liver.
[7] M. Vachon,et al. Salvage Therapy with Sofosbuvir/Velpatasvir/Voxilaprevir in DAA-experienced Patients: Results from a Prospective Canadian Registry. , 2021, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[8] J. Kao,et al. Sofosbuvir/velpatasvir for patients with chronic hepatitis C virus infection and compensated liver disease: real-world data in Taiwan , 2021, Hepatology International.
[9] M. Hellard,et al. Efficacy and safety of sofosbuvir/velpatasvir/voxilaprevir for HCV NS5A-inhibitor experienced patients with difficult to cure characteristics. , 2020, Clinical Infectious Diseases.
[10] J. Pawlotsky,et al. EASL recommendations on treatment of hepatitis C - Final update of the series. , 2020, Journal of hepatology.
[11] Ding‐Shinn Chen,et al. Sofosbuvir/velpatasvir/voxilaprevir plus ribavirin for chronic hepatitis C patients with direct acting antiviral failures: Implications for viral elimination in Taiwan. , 2020, Journal of the Formosan Medical Association = Taiwan yi zhi.
[12] D. Dieterich,et al. Efficacy of sofosbuvir/velpatasvir/voxilaprevir in direct-acting antiviral experienced patients with hepatitis C virus. , 2020, European journal of gastroenterology & hepatology.
[13] I. Ntalla,et al. Global real‐world evidence of sofosbuvir/velpatasvir as simple, effective HCV treatment: Analysis of 5552 patients from 12 cohorts , 2020, Liver international : official journal of the International Association for the Study of the Liver.
[14] F. Negro,et al. Real-world effectiveness and safety of glecaprevir/pibrentasvir for the treatment of patients with chronic HCV infection: a meta-analysis. , 2020, Journal of hepatology.
[15] F. Girardin,et al. Direct‐acting antiviral interactions with opioids, alcohol or illicit drugs of abuse in HCV‐infected patients , 2020, Liver international : official journal of the International Association for the Study of the Liver.
[16] A. Alberti,et al. Real-life effectiveness and safety of sofosbuvir/velpatasvir/voxilaprevir in hepatitis C patients with previous daa failure. , 2019, Journal of hepatology.
[17] Ding‐Shinn Chen,et al. Evolution of eGFR in chronic HCV patients receiving sofosbuvir-based or sofosbuvir-free direct acting antivirals. , 2019, Journal of hepatology.
[18] Ding‐Shinn Chen,et al. Glecaprevir/pibrentasvir for patients with chronic hepatitis C virus infection: Real‐world effectiveness and safety in Taiwan , 2019, Liver international : official journal of the International Association for the Study of the Liver.
[19] M. Buti,et al. Effectiveness and Safety of Sofosbuvir/Velpatasvir/ Voxilaprevir in Patients with Chronic Hepatitis C Previously Treated with DAAs. , 2019, Journal of hepatology.
[20] B. Pearlman,et al. Sofosbuvir/Velpatasvir/Voxilaprevir for Previous Treatment Failures With Glecaprevir/Pibrentasvir in Chronic Hepatitis C Infection. , 2019, The American journal of gastroenterology.
[21] H. Masur,et al. A Pilot Study of Safety and Efficacy of HCV Retreatment with sofosbuvir/velpatasvir/voxilaprevir in Patients With or Without HIV (RESOLVE STUDY). , 2019, Journal of hepatology.
[22] E. Gane,et al. Sofosbuvir/Velpatasvir/Voxilaprevir for patients with HCV who previously received a Sofosbuvir/Velpatasvir‐containing regimen: Results from a retreatment study , 2019, Journal of viral hepatitis.
[23] Ding‐Shinn Chen,et al. Real-world effectiveness and safety of sofosbuvir and ledipasvir with or without ribavirin for patients with hepatitis C virus genotype 1 infection in Taiwan , 2018, PloS one.
[24] M. Kumar,et al. APASL clinical practice recommendation: how to treat HCV-infected patients with renal impairment? , 2018, Hepatology International.
[25] M. Manns,et al. No impact of resistance-associated substitutions on the efficacy of sofosbuvir, velpatasvir, and voxilaprevir for 12 weeks in HCV DAA-experienced patients. , 2018, Journal of hepatology.
[26] J. Kao,et al. Comorbidities, concomitant medications and potential drug‐drug interactions with interferon‐free direct‐acting antiviral agents in hepatitis C patients in Taiwan , 2018, Alimentary pharmacology & therapeutics.
[27] R. Fontana,et al. Hepatitis C Guidance 2018 Update: AASLD-IDSA Recommendations for Testing, Managing, and Treating Hepatitis C Virus Infection. , 2018, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[28] M. Manns,et al. Deferred treatment with sofosbuvir-velpatasvir-voxilaprevir for patients with chronic hepatitis C virus who were previously treated with an NS5A inhibitor: an open-label substudy of POLARIS-1. , 2018, The lancet. Gastroenterology & hepatology.
[29] E. Deeks,et al. Sofosbuvir/Velpatasvir/Voxilaprevir: A Review in Chronic Hepatitis C , 2018, Drugs.
[30] Ding‐Shinn Chen,et al. Real‐world effectiveness and safety of paritaprevir/ritonavir, ombitasvir, and dasabuvir with or without ribavirin for patients with chronic hepatitis C virus genotype 1b infection in Taiwan , 2018, Journal of Gastroenterology and Hepatology.
[31] T. Asselah,et al. Glecaprevir–Pibrentasvir for 8 or 12 Weeks in HCV Genotype 1 or 3 Infection , 2018, The New England journal of medicine.
[32] M. Manns,et al. Sofosbuvir, Velpatasvir, and Voxilaprevir for Previously Treated HCV Infection , 2017, The New England journal of medicine.
[33] Ding‐Shinn Chen,et al. Hepatitis B Virus Reactivation in Patients Receiving Interferon-Free Direct-Acting Antiviral Agents for Chronic Hepatitis C Virus Infection , 2017, Open forum infectious diseases.
[34] G. Ioannou,et al. Effectiveness of Sofosbuvir, Ledipasvir/Sofosbuvir, or Paritaprevir/Ritonavir/Ombitasvir and Dasabuvir Regimens for Treatment of Patients With Hepatitis C in the Veterans Affairs National Health Care System. , 2016, Gastroenterology.
[35] V. Soriano,et al. Prevention and management of treatment failure to new oral hepatitis C drugs , 2016, Expert opinion on pharmacotherapy.
[36] M. Kumar,et al. APASL consensus statements and recommendation on treatment of hepatitis C , 2016, Hepatology International.
[37] T. Asselah,et al. Sofosbuvir and Velpatasvir for HCV Genotype 1, 2, 4, 5, and 6 Infection. , 2015, The New England journal of medicine.
[38] J. Feld,et al. Hepatitis C virus infection , 2015, Canadian Medical Association Journal.
[39] Ding‐Shinn Chen,et al. Comparison of Abbott RealTime HCV Genotype II with Versant Line Probe Assay 2.0 for Hepatitis C Virus Genotyping , 2015, Journal of Clinical Microbiology.
[40] Stefan Zeuzem,et al. Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection. , 2014, The New England journal of medicine.
[41] J. Kao,et al. Nanomedicines in the treatment of hepatitis C virus infection in Asian patients: optimizing use of peginterferon alfa , 2014, International journal of nanomedicine.
[42] Eoin Coakley,et al. Treatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin. , 2014, The New England journal of medicine.
[43] M. Niemi,et al. Impact of OATP transporters on pharmacokinetics , 2009, British journal of pharmacology.
[44] J. Montaner,et al. Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfection , 2006, Hepatology.
[45] A. Zanella,et al. Updated Definitions of Healthy Ranges for Serum Alanine Aminotransferase Levels , 2002, Annals of Internal Medicine.